Mesenchymal Stem Cells and Uses Therefor
AssigneeMesoblast International Sarl
InventorsSudeepta Aggarwal, Mark F. Pittenger, Timothy Varney
Life of this patent
Estimating the term…
Abstract
Methods of treating autoimmune diseases, allergic responses, cancer, or inflammatory diseases in an animal, promoting would healing, repairing epithelial damage and promoting angiogenesis in an organ or tissue of an animal by administering to the animal mesenchymal stem cells in an effective amount.
Claims25
1-13. (canceled)
A method of reducing inflammation in a human in need thereof, comprising the step of intravenously or intraarterially administering to a human having inflammation a suspension of cells in an amount effective to reduce the inflammation, wherein the cells are allogeneic mesenchymal stem cells, wherein the suspension of mesenchymal stem cells is at least about 95% homogeneous and wherein the mesenchymal stem cells express CD73 and CD105.
A method of reducing inflammation in the gastrointestinal track of a patient in need thereof, comprising the step of intravenously or intraarterially administering to a human suffering from inflammation of the gastrointestinal track a suspension of cells in an amount effective to reduce the inflammation, wherein the cells are allogeneic mesenchymal stem cells, wherein the suspension of mesenchymal stem cells is at least 95% homogeneous and wherein the mesenchymal stem cells express CD73 and CD105.
A method of increasing production or secretion of an anti-inflammatory cytokines interleukin-4 or interleukin-10 in a human in need thereof, comprising the step of:
- administering to the human a suspension of cells in an amount effective to increase production or secretion of the anti-inflammatory cytokines, wherein the cells are allogeneic mesenchymal stem cells that express cell surface markers CD73 and CD105 and wherein the suspension of mesenchymal stem cells is at least about 95% homogeneous.
A method of reducing production or secretion of a pro-inflammatory cytokine in a human in need thereof, comprising the steps of:
- administering to the human a suspension of cells in an amount effective to reduce production or secretion of the pro-inflammatory cytokine tumor necrosis factor alpha, interferon gamma or interleukin-17, wherein the cells are allogeneic mesenchymal stem cells expressing cell surface markers CD73 and CD105 and wherein the suspension of mesenchymal stem cells is at least 95% homogeneous.
A cell preparation comprising allogeneic adult mesenchymal stem cells in a dose effective to treat an inflammatory response in a subject in need thereof, wherein the adult mesenchymal stem cells are at least 95% homogeneous and express the cell surface markers CD73 and CD105.
Dependencies are inferred from the claim text.